Author | David Schenkein, MD | OncLive

Author | David Schenkein, MD

Articles

Dr. Schenkein on AG-221 for the Treatment of AML

April 08, 2014

David Schenkein, MD, Chief Executive Officer, Agios Pharmaceuticals, discusses AG-221 for the treatment of acute myeloid leukemia (AML).

x